Case report: a unique pediatric case of a primary CD8 expressing ALK-1 positive anaplastic large cell lymphoma of skeletal muscle
© Gaiser et al; licensee BioMed Central Ltd. 2012
Received: 23 February 2012
Accepted: 12 April 2012
Published: 12 April 2012
Primary involvement of skeletal muscle is a very rare event in ALK-1 positive anaplastic large cell lymphoma (ALCL). We describe a case of a 10-year old boy presenting with a three week history of pain and a palpable firm swelling at the dorsal aspect of the left thigh. Histological examination of the lesion revealed a tumoral and diffuse polymorphic infiltration of the muscle by large lymphoid cells. Tumor cells displayed eccentric, lobulated "horse shoe" or "kidney-shape" nuclei. The cells showed immunohistochemical positivity for CD30, ALK-1, CD2, CD3, CD7, CD8, and Perforin. Fluorescence in situ hybridization analysis revealed a characteristic rearrangement of the ALK-1 gene in 2p23 leading to the diagnosis of ALK-1 positive ALCL. Chemotherapy according to the ALCL-99-NHL-BFM protocol was initiated and resulted in a complete remission after two cycles. This case illustrates the unusual presentation of a pediatric ALCL in soft tissue with a good response to chemotherapy.
Anaplastic large cell lymphoma (ALCL) was discovered by Stein et al. and characterized by strong expression of the Ki-1 (CD30) antigen . In 1988, ALCL was included in the revised Kiel classification and is nowadays classified as a Non-Hodgkin lymphoma of T-cell origin by the World Health Organization [2, 3]. The key moment in understanding the primary biological driver behind ALCL was the discovery of the recurrent t(2;5)(p23;q35) translocation in this lymphoma type . This finding was further elucidated by Morris and colleagues who identified the two genes involved in this translocation: the anaplastic lymphoma kinase (ALK-1) on chromosome 2 and nucleophosmin (NPM1) on chromosome 5 . Subsequently, the NPM-ALK fusion protein was proven to have oncogenic capacity . Among the four main types of pediatric non-Hodgkin lymphoma (Burkitt lymphoma, diffuse large B-cell lymphoma, anaplastic large cell lymphoma and lymphoblastic lymphoma) ALCL has the best prognosis: event-free and overall survival rates were 72% and 88%, respectively, even in advanced-stage diseases .
Here, we report a case of a 10-year old boy diagnosed with an ALK-1 positive anaplastic large cell lymphoma of the skeletal muscle. Primary involvement of skeletal muscle by ALCL is extremely rare and so far only four pediatric cases have been reported in the literature [8–11].
Initial presentation and management
Materials and methods
Four micron tissue sections were stained with the following monoclonal antibodies: CD2, CD7, CD20, CD30, CD31, CD79, CD99, CD117, Alk-1, Desmin, D2-40, EMA, Ki67, TdT (all Dako Cytomation, Glostrup; Denmark), CD3, βF1 (T-cell receptor beta chains) (both Thermo Fisher Scientific, Waltham, MA, USA), CD5, CD8, CD10, CD56, Perforin (Leica, Wetzlar, Germany), and CD34 (Immunotech, Glendale, CA, USA). Antibody binding was visualized using the Envision System as described by the manufacturer.
In situ hybridization
In situ hybridization analyses for the t(2;5) translocation and for Epstein-Barr virus (EBV) encoded small nuclear RNAs (EBERs) was performed on four micron sections of formalin fixed, paraffin-embedded tissue paraffin sections using the ALK Dual Color, Break Apart Rearrangement Probe (Abbott, North Chicago, IL, USA) and ZytoFast™ EBV Probe (ZytoVision GmbH, Bremerhaven, Germany); procedures were performed according to the manufacturers' indications.
ALCL can be classified into ALK-1 negative and ALK-1 positive ALCL. ALK-1 negative ALCL occurs mainly in older patients (peak incidence ~ 60 y) and in advanced-stage disease. ALK-1 positive ALCL is a clinically aggressive lymphoma that mostly occurs in the first three decades of life . However, overall survival and longer disease free survival is observed after treatment with aggressive chemotherapy. Patients affected by ALK-1 positive ALCL have a significant better overall survival than ALK-1 negative ALCL patients (5-year overall survival: 70-80% vs. 33-49%) [14, 15]. It is still controversially discussed if this observation can be explained by the biological role of the ALK-1 fusion proteins or by the younger age of the ALK-1 positive ALCL patients. Unlike ALK-1 positive ALCL, which is characterized by t(2;5)(p23;q35) translocation and resulting in the expression of the NPM-ALK-1 fusion protein, so far no recurrent cytogenetic alterations have been described in ALK-1 negative ALCL.
The presented case illustrates a CD30+, ALK-1+ ALCL of T-cell origin (CD2-/+, CD3+, CD7+, CD8+ and Perforin+) in a pediatric patient. Due to the abundance of small neoplastic cells with pale cytoplasm mixed with some medium-sized and large lymphoid cells this case is best counted among the "small cell variant" of ALCL (10%). Other ALCL subcategories are the common (70-80%) and lymphohistiocytic type (10%).
Primary malignant lymphoma of soft tissue is an infrequent, and often diagnostically challenging neoplasm [16, 17]. Among those studies which reported the T- or B-cell phenotype of primary soft tissue lymphoma, B-cell accounted for over 90%. Most of those cases showed aggressive histology and were of diffuse large B-cell phenotype . T cell lymphomas in general and ALCL in particular exceedingly rarely exhibit primary infiltration of skeletal muscle [8–10]. Of note, all intramuscular primary ALCL cases reported so far have been ALK-1 positive. Why this T-cell lymphoma could overcome the normally well established protection of skeletal muscle against lymphocytic infiltration is unknown .
Interestingly, the current ALCL is the first among the reported intra-muscular ALCL primaries to show a CD8 phenotype, which is extremely rare in ALCL. However, trauma, which theoretically could have acted as a stimulatory trigger providing signals for T cell homing to skeletal muscle  was denied by the patient. Moreover, no other infectious or autoimmune process was known from the history or the local findings.
It should also be mentioned in this context that the slightly enlarged lymph nodes were only detected after MRI examination and were not clinically indicative. Unfortunately a lymph node biopsy was not performed. Therefore, a final statement about a possible secondary involvement of the muscle was not possible. However, we consider this possibility less likely because the majority of ALCL patients (70%) presents with advanced stage III to IV disease , which was obviously not the case in our patient.
ALCL has to be distinguished from classical Hodgkin lymphoma (cHL), CD30+ non-Hodgkin B cell lymphomas and very rare ALK-1 positive (and eventually CD30-negative) large B cell lymphomas. Differential diagnosis between ALCL and cHL can be made by expression of cytotoxic molecules such as Granzyme B, Perforin and T-cell-restricted intracellular antigen-1 (TIA1), EMA and CD45/LCA which are typical of ALCL, while positivity for CD15 (in 70% of cases), PAX5 (90%) and LMP1 (in 50%) are typical of cHL. To distinguish ALCL from ALK-1-positive large B cell lymphomas the lack of CD30 expression is critical and the t(2;5) translocation cannot be demonstrated in the B cell lymphoma .
We conclude that this case represents a very rare manifestation of an ALCL in soft tissue. Despite the anaplastic appearance a favorable outcome was possible after promptly applying aggressive chemotherapy. The expression of the NMP-ALK-1 protein and the young age of the patient might have influenced the positive outcome.
Written informed consent was obtained from the patient, respectively the guardians for publication of this case report and accompanying images. A copy of the written consent is available for review to the Editor-in-Chief of this journal.
- Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, et al.: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985, 66: 848-858.PubMedGoogle Scholar
- Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, van Unnik JA, Mioduszewska O, et al.: Updated Kiel classification for lymphomas. Lancet. 1988, 1: 292-293.View ArticlePubMedGoogle Scholar
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC. 2008, FourthGoogle Scholar
- Fischer P, Nacheva E, Mason DY, Sherrington PD, Hoyle C, Hayhoe FG, Karpas A: A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988, 72: 234-240.PubMedGoogle Scholar
- Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, Look AT, Saltman DL: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1995, 267: 316-317.View ArticlePubMedGoogle Scholar
- Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW: Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood. 1997, 90: 2901-2910.PubMedGoogle Scholar
- Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB: Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005, 23: 541-547.View ArticlePubMedGoogle Scholar
- Driss M, Abbes I, Mrad K, Sassi S, Oubich F, Barsaoui S, Romdhane KB: Primary CD30/ALK-1 positive anaplastic large cell lymphoma of the skeletal muscle in a child. Pathologica. 2009, 101: 97-100.PubMedGoogle Scholar
- Ishii E, Honda K, Nakagawa A, Urago K, Oshima K: Primary CD30/Ki-1 positive anaplastic large cell lymphoma of skeletal muscle with der(17)t(1;17)(q11;p11). Cancer Genet Cytogenet. 2000, 122: 116-120. 10.1016/S0165-4608(00)00285-5.View ArticlePubMedGoogle Scholar
- Wu L, Wang Y, Fu SL, Huang L, Tongji FC, Qi JY: Anaplastic large cell lymphoma with primary involvement of skeletal muscle: a rare case report and review of the literature. Pediatr Hematol Oncol. 2009, 26: 142-149. 10.1080/08880010902771531.View ArticlePubMedGoogle Scholar
- Kounami S, Shibuta K, Yoshiyama M, Mitani Y, Watanabe T, Takifuji K, Yoshikawa N: Primary Anaplastic Large Cell Lymphoma of the Psoas Muscle: A Case Report and Literature Review. Acta Haematol. 2012, 127: 186-188. 10.1159/000335744.View ArticlePubMedGoogle Scholar
- Murphy SB: Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980, 7: 332-339.PubMedGoogle Scholar
- Bishara MR, Ross C, Sur M: Primary anaplastic large cell lymphoma of the breast arising in reconstruction mammoplasty capsule of saline filled breast implant after radical mastectomy for breast cancer: an unusual case presentation. Diagn Pathol. 2009, 4: 11-10.1186/1746-1596-4-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, et al.: ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008, 111: 5496-5504. 10.1182/blood-2008-01-134270.View ArticlePubMedGoogle Scholar
- Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000, 96: 3681-3695.PubMedGoogle Scholar
- Recavarren RA, Yang J: Cytomorphologic features of primary anaplastic large cell lymphoma of the psoas muscle: a case report and literature review. Diagn Cytopathol. 2010, 38: 208-212.PubMedGoogle Scholar
- Chim CS, Loong F, Ooi GC, Srivastava G, Liang R: Primary skeletal muscle lymphoma. Am J Med. 2002, 112: 79-80. 10.1016/S0002-9343(01)00916-0.View ArticlePubMedGoogle Scholar
- Wiendl H, Mitsdoerffer M, Weller M: Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. Hum Immunol. 2003, 64: 1050-1056. 10.1016/j.humimm.2003.07.001.View ArticlePubMedGoogle Scholar
- Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW, Mason DY: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood. 1997, 89: 1483-1490.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.